MoneyWorks4Me

Zydus Lifesciences informs about press release

06 Oct 2022 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated October 6, 2022, titled ‘Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1242.00
Cipla 1331.00
Lupin 1953.75
Zydus Lifesciences 1113.00
View more..